FDC Ltd.
Fundamentals
- Market cap
- ₹6,648 cr
- P/E
- 23.62×
- ROE
- 11.70%
- Debt / equity
- 0.00
- 52-week range
- 312.95 — 527.80
Company snapshot
FDC Ltd.
Pharmaceuticals
₹6,843 cr
P/E 24.32×
Latest quarter · Mar 2026
Sales₹585 cr
Net profit₹103 cr
Op. margin+18.2%
EPS₹6.35
Strength & growth
Debt / equity0.00×
Current ratio2.31×
Sales CAGR+8.1%
EPS CAGR+6.3%
The timeline — 4 notes on FDC Ltd.
May 2026
- 27 May 26 · 3:42 PM IST Brief Brief · Earnings · Mid cap
FDC's US formulations leap 283% in Q4, but the year was flat
A strong final quarter, powered by a US FDA approval and margin recovery, couldn't offset a sluggish domestic year for FDC. Revenue rose just **3%** for FY26.
- 27 May 26 · 3:27 PM IST Brief Brief · Earnings · Mid cap
FDC Ltd. closes FY26 with modest growth and a strong Q4 finish
Standalone revenue climbed 2.7% to ₹2,126.33 crore for the year, while Q4 profit jumped 122% as the company absorbed a one-time labour charge.
- 27 May 26 · 3:15 PM IST Brief Brief · Earnings · Mid cap
FDC ends FY26 with 2.7% revenue growth as Q4 profit surges
FDC reported a strong final quarter with revenue up 17% and profit up 122%, though annual figures remained modest.